InvestorsObserver
×
News Home

Should Biotechnology Stock Odonate Therapeutics Inc (ODT) Be in Your Portfolio Friday?

Friday, April 09, 2021 01:49 PM | InvestorsObserver Analysts

Mentioned in this article

Should Biotechnology Stock Odonate Therapeutics Inc (ODT) Be in Your Portfolio Friday?

The 15 rating InvestorsObserver gives to Odonate Therapeutics Inc (ODT) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 10 percent of stocks in the Biotechnology industry, ODT’s 15 overall rating means the stock scores better than 15 percent of all stocks.

Overall Score - 15
ODT has an Overall Score of 15. Find out what this means to you and get the rest of the rankings on ODT!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 15 would rank higher than 15 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Odonate Therapeutics Inc Stock Today?

Odonate Therapeutics Inc (ODT) stock is trading at $3.78 as of 1:46 PM on Friday, Apr 9, a rise of $0.26, or 7.41% from the previous closing price of $3.52. The stock has traded between $3.40 and $4.06 so far today. Volume today is 7,354,390 compared to average volume of 7,683,516.

Click Here to get the full Stock Score Report on Odonate Therapeutics Inc (ODT) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App